Physician profile
Bridgit V Wedgle
NPI 1609402817
$1,653.63
in general payments reported to CMS, 2019-2025
32 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.64 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.83 | 2025 | |
| Stemline Therapeutics INC. | $147.16 | 2025 | Orserdu |
| Janssen Biotech, INC. | $124.35 | 2025 | Rybrevant, Erleada, Akeega |
| Astellas Pharma US INC | $103.26 | 2025 | Vyloy, Padcev |
| Novartis Pharmaceuticals Corporation | $93.33 | 2025 | |
| Sobi, INC | $91.84 | 2025 | |
| Glaxosmithkline, LLC. | $85.56 | 2025 | Jemperli, Ojjaara, Zejula |
| Seagen INC. | $74.99 | 2025 | |
| Incyte Corporation | $71.25 | 2025 | Jakafi, Niktimvo, Monjuvi |
| Merck Sharp & Dohme LLC | $56.47 | 2025 | Keytruda, Welireg |
| Pfizer INC. | $54.76 | 2025 | |
| Caris Mpi, INC. | $54.61 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $53.97 | 2025 | Imfinzi |
| Gilead Sciences, INC. | $52.21 | 2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $35.19 | 2025 | Libtayo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.79 | 2025 | Enhertu |
| Adaptive Biotechnologies Corporation | $29.57 | 2025 | Clonoseq |
| Alnylam Pharmaceuticals INC. | $28.75 | 2025 | Givlaari |
| Tersera Therapeutics LLC | $28.30 | 2025 | Xermelo |
| Bayer Healthcare Pharmaceuticals INC. | $26.19 | 2025 | |
| Nuvation Bio INC. | $25.30 | 2025 | Ibtrozi |
| Sumitomo Pharma America, INC. | $25.18 | 2025 | Orgovyx |
| Azurity Pharmaceuticals, INC. | $24.07 | 2025 | Danziten |
| Rigel Pharmaceuticals, INC. | $22.20 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Eisai INC. | $22.02 | 2025 | |
| Exelixis INC. | $20.44 | 2025 | Cabometyx |
| Springworks Therapeutics, INC. | $19.19 | 2025 | Ogsiveo |
| Recordati_rare_diseases_inc. | $19.00 | 2025 | Sylvant |
| Puma Biotechnology, INC. | $16.90 | 2025 | |
| Novocure INC. | $16.46 | 2025 | Optune Gio |
| Genentech USA, INC. | $16.27 | 2025 | Itovebi |
| Taiho Oncology, INC. | $14.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgit Wedgle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.